DAAs for chronic hepatitis C: good public health investment in Vietnam

2020 ◽  
Vol 859 (1) ◽  
pp. 11-11
Keyword(s):  
Public Health ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Health Investment

scholarly journals Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Rodolfo Castro ◽  
Hugo Perazzo ◽  
Beatriz Grinsztejn ◽  
Valdilea G. Veloso ◽  
Chris Hyde
Keyword(s):  
Public Health ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Public Health Issue ◽  
Advanced Fibrosis ◽  
Noninvasive Methods ◽  
Treatment Protocols ◽  
Major Public Health Issue ◽  
Effectiveness Analysis

Chronic hepatitis C remains one of the main causes of chronic liver disease worldwide and presents a variable natural history ranging from minimal changes to advanced fibrosis and cirrhosis and its complications, such as development of hepatocellular carcinoma. Approximately, 1.45 million people are estimated to be infected by HCV in Brazil representing a major public health issue. The aim of this paper was to review the epidemiology and management of chronic hepatitis C from a Brazilian perspective. The management of chronic hepatitis C has been challenged by the use of noninvasive methods to stage liver fibrosis as an alternative to liver biopsy and the high cost of new interferon-free antiviral treatments. Moreover, the need of cost-effectiveness analysis in hepatitis C and the recent changes in treatment protocols were discussed.

scholarly journals 1270. Population-Based Estimates of PrEP Access in Oregon, 2012–2016

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S457-S457
Author(s):  
Timothy William Menza ◽  
Jeff Capizzi
Keyword(s):  
Public Health ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Rural Areas ◽  
Population Based ◽  
Hiv Diagnosis ◽  
Early Syphilis ◽  
Administrative Dataset ◽  
Number Of Individuals

Abstract Background PrEP is an important HIV prevention modality. Population-based metrics of PrEP uptake and access are critical to the evaluation of public health efforts to increase PrEP use. Methods Using the Oregon All Payers All Claims administrative dataset, we determined the number of unique individuals at least 16 years of age starting PrEP, defined as at least one prescription of >30 days of Truvada, each year from 2012–2016. People with HIV or hepatitis B were excluded. We created two metrics of PrEP access in 2016: the number of individuals starting PrEP per 100K population and the number of individuals with a PrEP prescription in each of the four quarters of 2016 per 100K population (i.e., prevalent users). Using public health surveillance data, we created three metrics of PrEP need in 2016: the number of HIV diagnoses per 100K population; the number early syphilis and gonorrhea diagnoses per 100K population; and the number of acute or chronic hepatitis C diagnoses among patients aged 16–30 years per 100K population. We calculated six metrics of PrEP access-to-need by dividing each of the access measures by the need measures. Results The number of individuals with a new PrEP prescription increased from 8 in 2012 to 571 in 2016. Most new PrEP users were men, aged 25–34 years, identified as white, lived in an urban area, had commercial insurance, and had an internal medicine PrEP prescriber. In 2016, there were 17.2 PrEP starts and 9.9 individuals with a PrEP prescription in all four quarters of 2016 per 100K population. There were 6.7 HIV cases, 136.0 early syphilis and gonorrhea cases, and 109.1 acute and chronic hepatitis C cases per 100K population. Per HIV diagnosis, there were 2.6 PrEP starts and 1.5 prevalent users. However, there were 0.13 PrEP starts and 0.07 prevalent users per early syphilis and gonorrhea diagnosis and 0.16 PrEP starts and 0.09 prevalent users per hepatitis C diagnosis. Women, people aged 16–24, people of color, and people in rural areas experienced lower PrEP access-to-need. Conclusion Access metrics based on prevalent users (a measure of longer-term adherence to PrEP), STI diagnoses (a measure of HIV acquisition risk), and HCV diagnoses among those less than 30 years of age (a measure of need among people who inject drugs) may provide a more complete assessment of PrEP access-to-need than those based on PrEP starts and HIV diagnoses. Disclosures All authors: No reported disclosures.

Comparing the public health burden of chronic hepatitis C and HIV infection in France

2004 ◽  
Vol 40 (2) ◽  
pp. 319-326 ◽  
Author(s):  
Sylvie Deuffic-Burban ◽  
John B Wong ◽  
Alain-Jacques Valleron ◽  
Dominique Costagliola ◽  
Jean-François Delfraissy ◽  
...  
Keyword(s):  
Public Health ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Hiv Infection ◽  
Chronic Hepatitis C ◽  
Public Health Burden ◽  
The Public ◽  
Health Burden

scholarly journals Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil

2018 ◽  
Vol 22 (4) ◽  
pp. 317-322 ◽  
Author(s):  
Iandra Holzmann ◽  
Cristiane V. Tovo ◽  
Roseline Minmé ◽  
Mônica P. Leal ◽  
Michele P. Kliemann ◽  
...  
Keyword(s):  
Public Health ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Health System ◽  
Chronic Hepatitis C ◽  
Public Health System ◽  
Direct Acting Antivirals ◽  
Hepatitis C Treatment ◽  
The Public ◽  
Direct Acting

scholarly journals TRIPLE THERAPY IN CHRONIC HEPATITIS C: initial series in a public health program in the South of Brazil

2015 ◽  
Vol 52 (1) ◽  
pp. 14-17 ◽  
Author(s):  
Paulo R L ALMEIDA ◽  
Carla Bortolin FONSECA ◽  
Vivian W KOCH ◽  
Amanda M SOUZA ◽  
Alberi A FELTRIN ◽  
...  
Keyword(s):  
Public Health ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Triple Therapy ◽  
Chronic Hepatitis C ◽  
Virologic Response ◽  
Current Therapy ◽  
Genotype 1 ◽  
Number Of Patients ◽  
Clinical Series

Background Chronic hepatitis C has great impact on world’s health. Current therapy for genotype 1 hepatitis C virus includes protease inhibitors boceprevir and telaprevir, associated to standard therapy - peginterferon alfa + ribavirin. There are no published data in Brazil on the results of this new therapy, and it is interesting an evaluation of what was accomplished up to this moment. Objectives To evaluate virologic response to triple therapy, as well as the safety profile and tolerability. Method This study is a clinical series of patients receiving triple therapy for C hepatitis in a single center of a Public Health System of South Brasil. Out of the 121 patients that initiated the triple therapy, the first patients that finished the treatment and evaluated the sustained virological response (24 weeks after the end of treatment) were included. Results Twenty four genotype 1 chronic hepatitis C monoinfected patients were included. Nineteen (79.2%) patients had been previously treated. Thirteen (54.2%) patients were cirrhotic. Nineteen (79.2%) patients completed the planned therapy. By the end of the treatment, 14 (58.3%) out of 24 patients had undetectable viral load. Sustained virologic response occurred in 12 (50.0%) out of 24 patients, 07 (58.3%) in telaprevir group and 05 (41.7%) in boceprevir group. Out of 24 patients under triple therapy, 58% (n=14) presented anemia. Conclusions In conclusion, despite the small number of patients treated with triple therapy evaluated in the current study, it possibly reflects the population under this therapy in real-life.

Sign in / Sign up

Export Citation Format

Share Document